4-Methylmorpholine → 1-[5-(5-fluoro-2-{1-[2-(4-methyl-1,4-diazepan-1-yl)-2-oxoethyl]-1H-pyrazol-4-yl}-1H-pyrrolo[2,3-b]pyridin-4-yl)-1,3-thiazol-2-yl]cyclobutanol

HRID 2362690노트

반응식

HRID 2362690 반응식
[F:1][C:2]1[C:3]([C:20]2[S:24][C:23]([C:25]3([OH:29])[CH2:28][CH2:27][CH2:26]3)=[N:22][CH:21]=2)=[C:4]2[CH:10]=[C:9]([C:11]3[CH:12]=[N:13][N:14]([CH2:16][C:17](O)=[O:18])[CH:15]=3)[NH:8][C:5]2=[N:6][CH:7]=1.[CH3:30][N:31]1[CH2:37][CH2:36][CH2:35][NH:34][CH2:33][CH2:32]1.CN1CCOCC1.O.ON1C2C=CC=CC=2N=N1.Cl.CN(C)CCCN=C=NCC>CN(C)C=O.CS(C)=O>[F:1][C:2]1[C:3]([C:20]2[S:24][C:23]([C:25]3([OH:29])[CH2:28][CH2:27][CH2:26]3)=[N:22][CH:21]=2)=[C:4]2[CH:10]=[C:9]([C:11]3[CH:12]=[N:13][N:14]([CH2:16][C:17]([N:34]4[CH2:35][CH2:36][CH2:37][N:31]([CH3:30])[CH2:32][CH2:33]4)=[O:18])[CH:15]=3)[NH:8][C:5]2=[N:6][CH:7]=1

참가 물질

8

반응물 5

HCID 79724-MethylmorpholineHCID 2283491-MethylhomopiperazineHCID 27239391,3-Propanediamine, N'-(ethylcarbonimidoyl)-N,N-dimethyl-, monohydrochlorideHCID 27960291-Hydroxybenzotriazole hydrateHCID 670037172-(4-(5-fluoro-4-(2-(1-hydroxycyclobutyl)thiazol-5-yl)-1H-pyrrolo[2,3-b]pyridin-2-yl)-1H-pyrazol-1-yl)acetic acid

생성물 1

HCID 546730971-[5-(5-fluoro-2-{1-[2-(4-methyl-1,4-diazepan-1-yl)-2-oxoethyl]-1H-pyrazol-4-yl}-1H-pyrrolo[2,3-b]pyridin-4-yl)-1,3-thiazol-2-yl]cyclobutanol

시약·촉매·용매 2

HCID 679Dimethyl Sulfoxide용매HCID 6228Dimethylformamide용매

실험 절차

To a solution of 2-(4-(5-fluoro-4-(2-(1-hydroxycyclobutyl)thiazol-5-yl)-1H-pyrrolo[2,3-b]pyridin-2-yl)-1H-pyrazol-1-yl)acetic acid (Example 65B) (100 mg, 0.242 mmol) in N,N-dimethylformamide (783 μl) was added 1-methyl-1,4-diazepane (35.9 mg, 0.314 mmol), 4-methylmorpholine (80 μl, 0.726 mmol), 1-hydroxybenzotriazole hydrate (55.6 mg, 0.363 mmol), and N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (69.6 mg, 0.363 mmol). The reaction was cooled to room temperature and diluted with dimethyl sulfoxide (1 mL). The resulting solution was purified by reverse phase high performance liquid chromatography (RP HPLC, 19×150 mm Atlantis Prep T3 OBD 5 um column, eluting with a gradient of 5% B in A to 75% B in A over 25 minutes, wherein A is water containing 0.1% v/v trifluoroacetic acid and B is acetonitrile containing 0.1% v/v trifluoroacetic acid) to give the title compound. 1H NMR (300 MHz, DMSO-d6) δ 12.29 (bs, 1H), 8.43 (s, 1H), 8.29 (s, 1H), 8.20 (d, J=3.6 Hz, 1H), 8.10 (s, 1H), 7.05 (s, 1H), 6.65 (s, 1H), 5.22-5.17 (m, 2H), 3.67-3.41 (m, 4H), 2.67-2.34 (m, 6H), 2.32-2.23 (m, 3H), 2.05-1.71 (m, 4H); MS ESI(+) m/z 510.1 [M+H]+.

후처리

  1. customThe resulting solution was purified by reverse phase high performance liquid chromatography (RP HPLC, 19×150 mm Atlantis Prep T3 OBD 5 um column
  2. washeluting with a gradient of 5% B in A to 75% B in A over 25 minutes

출처 및 근거

ORD 기록
ord-b8acefd9ad42471fbff6b8718ae54708
출처 데이터셋
uspto-grants-2014_04
특허 번호
US08691810B2

반응 노트

불러오는 중…